| |
Over our many years of preparing & filing FDA submissions, we have often encountered sponsors who cannot file a New Drug Application or Biologic License Application within expected timeframes; mostly due to a failure to start & complete prerequisite activities before the targeted filing date. Download our checklist to learn how to keep your NDA submission on track. 
|
|
Today’s Big NewsOct 23, 2023 |
| By Annalee Armstrong Daiichi Sankyo and AstraZeneca finally have some clarity on the deaths that occurred in two phase 3 studies for their Enhertu follow up Dato-DXd. The gist of the safety update is that more patients in the lung cancer study experienced a key adverse event when taking Dato-DXd compared to breast cancer. |
|
|
|
By Annalee Armstrong BioNTech’s new manufacturing process for CAR-T seems to have done the trick in boosting the potency of the solid tumor therapy BNT211, but that bit of extra juice seems to have upped the side effect profile as well. |
By Nick Paul Taylor Roche really was lining up a $7 billion challenge to Merck & Co. Months after a media report about a potential deal, the Swiss drugmaker has agreed to pay Roivant and Pfizer $7.1 billion upfront for regional rights to a bowel disease candidate that is on the cusp of phase 3. |
Sponsored by WCG The FDA and EMA recommend EACs and DMCs be independent from sponsors and CROs. Our industry expert shares how and when to select the right EAC providers and more to de-risk your clinical trials. |
By Annalee Armstrong,Max Bayer A nearly year-long clinical hold on Verve Therapeutics’ base editing therapy meant to treat a genetic form of high cholesterol has been lifted in the U.S., thanks to data from an ongoing human trial elsewhere in the world and some preclinical work that has allayed the FDA’s concerns. |
By James Waldron If it wasn’t enough for Cargo Therapeutics to raise $200 million and recruit a C-suite of biopharma veterans so far this year, the CAR-T-focused company is now eying up an IPO. |
By Annalee Armstrong MADRID—If Eli Lilly could simply offer an oral option in place of Faslodex for breast cancer, Jacob Van Naarden would be happy. Early evidence shows that the Indianapolis-based pharma’s oral SERD may be able to do that. |
By Annalee Armstrong Merck & Co. showcased early pharmacokinetic data from its KRAS G12C inhibitor MK-1084 at the European Society for Medical Oncology, suggesting the candidate may be able to find a way around some of the challenges that have troubled earlier entrants to the space. |
By Nick Paul Taylor Merck & Co. is pruning its pipeline of antibody-drug conjugates. Days after Merck paid $4 billion for three Daiichi Sankyo assets, Kelun-Biotech has revealed the Big Pharma has decided (PDF) to pass on two of its preclinical ADCs. |
By Annalee Armstrong Responses to Merus’ bispecific antibody in pancreatic and lung cancer are creeping higher with every data cut, giving CEO Bill Lundberg confidence that the dual American and Dutch biotech may someday be able to give a much-needed lifeline for one of the most difficult cancers out there. |
By Annalee Armstrong When patients reached Ambrx Biopharma’s phase 1/2 clinical trial for prostate cancer, they were nearing the end of their treatment journey. CEO Daniel O’Connor and Chief Clinical Officer Sandra Aung don’t take that lightly. |
By Gabrielle Masson GSK is the latest to partake in a string of recent antibody-drug conjugate deals, dishing out $85 million cash and up to $1.4 billion in biobucks for Hansoh Pharma’s gynecologic cancer asset. |
By Angus Liu As Novartis aims to move its radiotherapy Pluvicto into an earlier treatment setting in prostate cancer, it has posted a mixed bag of trial data that cast a cloud of uncertainty over its regulatory path forward. |
By Andrea Park Once again, Philips has been hit with an FDA Class I label for a correction to certain of its respiratory support devices. |
By Nick Paul Taylor Alright, alright, alright, Matthew McConaughey is lending his smooth Texan voice to a cancer awareness campaign. Working with Stand Up To Cancer (SU2C) and Visit Myrtle Beach, the Oscar-winning actor has created a public service announcement to raise awareness of the importance of funding cancer research. |
By Annalee Armstrong ESMO attendees arrived in Madrid to torrential downpours Thursday evening, a gloomy atmosphere that did not reflect the overall excitement of an industry conference that promised to showcase breakthroughs in breast, lung and prostate cancer. |
By Conor Hale Both companies have sought to build digital platforms with the ability to tap into patient communities and collect real-world information that could be useful to medical product designers and drug developers. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," Fierce's Fraiser Kansteiner engages in a conversation with Alexander Scott, senior vice president of integrity at Eisai, to discuss the full approval of Leqembi and what it means for Eisai and, most importantly, for Alzheimer's patients. |
|
|---|
|
|
|
You don’t have to choose between oversized and clean-and-reuse systems. There’s a system that’s fit-for-purpose — which scales all the way up to 200 L and beyond. See how. 
|
|
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
Whitepaper Cell and gene therapy development has exploded, with Q4 2022 showing more FDA approvals than over the past five years combined.[1] Sponsored by: Thermo Fisher Scientific |
Whitepaper Uncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
Webinar Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
Whitepaper Economic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
Whitepaper From Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
| Edison Ballroom, New York City |
|
|
| |
|
